patent.fyi
Applications  /  US 2026/0355130
United States Patent Application Publication

US 2026/0355130 A1

Published
Nov 12, 2026
Filed
May 9, 2025
Earliest date on the face
Jun 30, 2022
Classification
A61K 31/137
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Lower first dextromethorphan strength

What ifWhat if the first dosage form contains 20 mg of dextromethorphan and 105 mg of bupropion hydrochloride?
Claim language“about 30 mg of dextromethorphan”

A tablet press compresses a blend of both active ingredients, microcrystalline cellulose, and a disintegrant. The first tablet supplies 25 mg less dextromethorphan than the 45 mg second dosage form.

1.2Higher second dextromethorphan strength

What ifWhat if the second dosage form contains 60 mg of dextromethorphan and 105 mg of bupropion hydrochloride?
Claim language“about 45 mg of dextromethorphan”

A tablet press meters the two active ingredients into separate layers of a single tablet. The bupropion layer delivers the same amount as the first dosage form, and the dextromethorphan layer delivers 30 mg more.

1.3Single dose oral solutions

What ifWhat if both dosage forms are oral solutions with both active ingredients dissolved in each?
Claim language“a plurality of microparticles”

Water-soluble salts of both active ingredients dissolve in buffered water. Two concentrations of dextromethorphan supply the two strengths at a common fill volume, and sealed single-dose vials dispense the full volume.

1.4Larger median particle diameter

What ifWhat if the median particle diameter is 140 to 170 μm by laser diffraction?
Claim language“about 50 μm to about 100 μm”

A classified middle fraction supplies most of the particle volume, and smaller and larger fractions provide the lower and upper tails. Laser diffraction verifies the volume median after the fractions are blended.

1.5Larger lower percentile diameter

What ifWhat if the 10th percentile of particle diameter is 40 to 50 μm by laser diffraction?
Claim language“about 1 μm to about 30 μm”

An air classifier separates the finest particles from the feed. The retained fine fraction is blended with middle and coarse fractions so that 10 percent of the measured particle volume falls below a diameter of 40 to 50 μm.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference kit for instrument training

An analytical training kit contains separate sealed sets of the 105 mg bupropion hydrochloride and 30 mg dextromethorphan units and the 105 mg bupropion hydrochloride and 45 mg dextromethorphan units. A third compartment holds sealed aliquots from the microparticle lot used to make one set of units. Trainees disperse the reference aliquots in a laser diffraction instrument and compare the measured 10th, 50th, and 90th percentiles with the values recorded for the lot.

Component substitution

Particle sizing by dynamic imaging

A dynamic image analyzer replaces the laser diffraction instrument for characterization of the microparticle lot. A dry feeder spreads the particles across a backlit imaging zone, and a camera records their silhouettes. Software segments isolated silhouettes, calculates the diameter of a circle with the same projected area as each silhouette, and reports the 10th, 50th, and 90th percentiles of the resulting count distribution.

Parameter or scale variation

Microparticle lot with a smaller upper tail

The two dosage forms retain 105 mg of bupropion hydrochloride per unit and use 30 mg and 45 mg of dextromethorphan, respectively. The microparticle lot has laser diffraction targets of 15 to 25 μm at the 10th percentile, 55 to 75 μm at the median, and 130 to 170 μm at the 90th percentile. A vibratory sieve separates size fractions, and measured amounts of those fractions are recombined and checked by laser diffraction before the lot enters dosage form production.

Combination with existing systems

Kit integrated with pharmacy inventory

The two strengths occupy separate blister cards in one carton, with a two-dimensional barcode on each card and on the carton. The carton barcode identifies the kit, and each card barcode identifies the strength, lot, and expiration date. At stocking and dispensing, a scanner reads the codes and pharmacy inventory software verifies that the two card strengths match the kit record.

Blister line with strength verification

A blister packaging line fills and seals separate cards for the 30 mg and 45 mg dextromethorphan strengths, with 105 mg of bupropion hydrochloride in each dosage unit. A camera reads the printed strength and lot code on each sealed card as it enters the cartoning station. The cartoner places one card of each strength into a carton and diverts assemblies with unreadable codes or duplicate strengths.

Automated or data-driven variant

Automated sampling of microparticle lots

An automated sampler withdraws aliquots from a moving microparticle stream at scheduled intervals before the particles enter the dosage form blender. A dry dispersion module feeds each aliquot into a laser diffraction instrument, and the controller records the 10th, 50th, and 90th percentiles with the sample time and lot identifier. The controller flags the lot for review when a measured percentile falls outside its configured range.

Specific version of a part

Two layer compressed tablet

One tablet layer contains 105 mg of bupropion hydrochloride in a hydroxypropyl methylcellulose matrix. A second layer contains dextromethorphan hydrobromide in an amount that supplies 30 mg of dextromethorphan on a free-base basis, with croscarmellose sodium to promote disintegration.

Capsule with bupropion microparticles

A hard capsule contains bupropion hydrochloride microparticles blended with mannitol and dextromethorphan hydrobromide granules. The capsule shell dissolves after ingestion and releases the particulate fill.

Dry dispersion median measurement

A dry powder feeder disperses a representative sample in an air stream through a laser diffraction instrument. The instrument calculates the cumulative particle volume distribution and reports a median diameter of 75 μm.

Classified coarse particle fraction

A classified coarse fraction is blended with finer bupropion-containing microparticles. Laser diffraction verifies a 90th percentile diameter of 250 μm on a cumulative volume basis.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2020/0095386 A1
Published
Mar 26, 2020
Filed
May 25, 2019
Class
C08J 3/124
Document BUS 10,874,663 B2
Published
Dec 29, 2020
Filed
Mar 17, 2020
Class
A61K 31/485
Claim 1
Document A
Document B
1.1a first dosage form comprising about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, and about 30 mg of dextromethorphan, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan; and
The oral dosage form of embodiment 16, wherein about 30 mg to about 350 mg of dextromethorphan is present in the dosage form. The oral dosage form of embodiment 16 or 17, wherein about 100 mg to about 400 mg of bupropion is present in the dosage form.
B · US 10,874,663 B2 · ¶ 453
1.2a second dosage form comprising about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, and about 45 mg of dextromethorphan, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan,
The oral dosage form of embodiment 16, wherein about 30 mg to about 350 mg of dextromethorphan is present in the dosage form. The oral dosage form of embodiment 16 or 17, wherein about 100 mg to about 400 mg of bupropion is present in the dosage form.
B · US 10,874,663 B2 · ¶ 453
1.3wherein the first dosage form or the second dosage form contains a plurality of microparticles,
A panel of lotion formulations, thickened with microparticles of D,L-γ-poly(glutamate) cross-linked with the ethylene glycol diglycidyl ether (prepared similarly to Example 1) at dispersions of 0.25% w/v, 0.5% w/v, and 1% w/v, was prepared as per the following procedure: 1.
A · US 2020/0095386 A1 · ¶ 60
1.4wherein the plurality of microparticles has a median particle diameter of about 50 μm to about 100 μm as determined by laser diffraction,
The rheology modifier composition of this invention includes cross-linked poly(amino acid) particles with a mean equivalent spherical diameter (that is, diameter of a sphere of equivalent volume to the mean volume of the particles) when fully swollen in deionized water of up to about 1000 μm (measured by laser diffraction.
A · US 2020/0095386 A1 · ¶ 29
1.5wherein the 10th percentile of microparticle diameter of the plurality of microparticles is about 1 μm to about 30 μm as determined by laser diffraction, and
1.6wherein the 90th percentile of microparticle diameter of the plurality of microparticles is about 200 μm to about 300 μm as determined by laser diffraction.

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, the thickening potency of these materials is generally limited and may be adversely affected by an aqueous matrix composition; particularly, thickening potency is often reduced in the presence of electrolytes, especially polyvalent metal cations such Ca2+ and Mg2+.
A · US 2020/0095386 A1 · ¶ 6
There is thus a need to produce biobased, non-toxic, and biodegradable thickeners that can offer performance parity with conventional synthetic carboxyl-containing polymers based on ethylenically unsaturated monomers.
A · US 2020/0095386 A1 · ¶ 8
Some embodiments include a method of increasing dextromethorphan plasma levels in a human being, comprising co-administering bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds with dextromethorphan.
B · US 10,874,663 B2 · ¶ 2
Some embodiments include a method of reducing an adverse event associated with treatment by dextromethorphan, comprising co-administering threohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human patient in need of dextromethorphan treatment, wherein the human patient is at risk of experiencing the adverse event as a result of being treated with dextromethorphan.
B · US 10,874,663 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355130 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355130/, SHA-256 dc8f1136ad149a077be65b2ca8f34b2cbbc9ccd2b5c250516d22b1c48c775887
First published
Permanent addresshttps://patent.fyi/US20260355130/
Content fingerprint (SHA-256)dc8f1136ad149a077be65b2ca8f34b2cbbc9ccd2b5c250516d22b1c48c775887
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi